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Introduction
Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ), also known as platelet-activating factor acetylhydrolase (PAF-AH), is an enzyme expressed by activated inflammatory cells in atherosclerotic lesions, and found at high levels in unstable and ruptured plaques. 1 Lp-PLA 2 circulates in plasma bound predominantly to low-density lipoprotein (LDL) particles. 2 Although Lp-PLA 2 produces the proinflammatory mediators lysophosphatidylcholine and oxidized free fatty acids through hydrolysis of oxidized phospholipids on LDL, it also has anti-inflammatory activity through degradation of platelet-activating factor, 3 and its biological role in the initiation and progression of atherosclerosis is uncertain. 4 The Lp-PLA 2 inhibitor darapladib reduces Lp-PLA 2 activity by >60%; 5 however, two phase III trials in 28 854 patients with stable coronary heart disease (CHD) or acute coronary syndrome (ACS), with about 3 years of treatment, failed to establish a protective role of darapladib for prevention of further major vascular disease. 6, 7 Several epidemiological studies in mainly Western populations have examined the associations of Lp-PLA 2 mass and activity with risk of vascular diseases. A metaanalysis of 79 036 individuals from 32 prospective studies reported that one standard deviation higher Lp-PLA 2 activity was associated with 8-16% higher risk of occlusive vascular disease, after adjusting for conventional risk factors, with the effect on CHD being similar in magnitude to that of LDL-cholesterol or systolic blood pressure (SBP). 8 However, a study of 19 037 individuals with established occlusive vascular disease found no association between Lp-PLA 2 activity and coronary events after more extensive adjustment for lipids, 9 casting doubt on a causal role of Lp-PLA 2 in CHD. Functional genetic variants can be used to assess the causal role of proteins such as Lp-PLA 2 , and their potential value as therapeutic targets, in a manner analogous to a randomized controlled trial. 10 A c.835G > T (amino acid substitution V279F) variant in the PLA2G7 gene encoding Lp-PLA 2 inactivates the enzyme, resulting in about 50% lower Lp-PLA 2 activity for each copy of the loss-offunction variant.
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PLA2G7 V279F is rare in Europeans 14 but relatively common in East Asian populations, with the frequency ranging from $5% in Chinese 13 to 17% in Japanese. 15 However, previous studies of PLA2G7 V279F with vascular diseases in East Asians have produced conflicting findings. Two meta-analyses, each with about 3600 cases with some overlap, reported no apparent association with CHD risk. 16, 17 Subsequently, a study in Koreans reported a 20% lower risk of CHD associated with V279F among men (3700 cases) but no effect in women (1130 cases).
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Although Lp-PLA 2 activity might play a role in multiple biological pathways, studies examining the role of PLA2G7 V279F in diseases other than CHD, including other vascular diseases, are limited. We present findings from a large-scale study of over 90 000 adults from the China Kadoorie Biobank (CKB) prospective cohort, with health record linkage to a range of health outcomes. We previously reported a summary of the association of PLA2G7 V279F with vascular diseases in the CKB. 19 This study reports in detail the effects of the PLA2G7 V279F loss-of-function variant on pre-defined major vascular diseases as hypothesis-testing of the randomized trials of inhibition of Lp-PLA 2 , and further examines in a hypothesis-free approach the associations of PLA2G7 V279F with a phenome-wide range of other disease outcomes and traits.
Methods

Study population
The CKB design and methods are reported in detail elsewhere. 20 
Main outcome measures
The pre-specified primary outcome was incident major vascular events (MVE: vascular death, myocardial infarction, stroke). Secondary vascular outcomes were incident major coronary events (MCE: CHD death, myocardial infarction), major occlusive events (CHD death, myocardial infarction, ischaemic stroke), myocardial infarction, total stroke, ischaemic stroke, haemorrhagic stroke and vascular death. For all vascular outcomes, controls excluded individuals reporting a history of CHD, stroke or transient ischaemic attack at baseline, or incident MVE. Tertiary outcomes were diabetes and COPD, including both prevalent (previous history or screendetected 22, 23 ) and incident cases and incident chronic kidney disease, liver disease, inflammatory disease, cancer and nonvascular death. Controls excluded individuals reporting a history of that disease at baseline. Incident events in the range ICD-10: A00-N99 were grouped into 41 distinct categories, largely following the ICD-10 classification (events outside this range included external causes and were not considered relevant to the present study). For these ICD-10 categorized outcomes, no exclusions for prevalent diseases were made from controls. For all outcomes, no exclusions for prevalent diseases were made from cases, i.e. not all cases were new onset. There was overlap between the clinically defined primary, secondary and tertiary outcomes, and the ICD-10 categorized outcomes. All disease outcomes were ascertained through death and disease registries and health insurance records. Disease outcomes were pre-specified in a detailed analysis plan and are described in the supplementary material (available as Supplementary data at IJE online). Selected continuous traits measured at baseline were also assessed.
Statistical analyses
Baseline characteristics were standardized to the sex, age and region distribution of the study population, and compared across genotypes by a v 2 -test for categorical measures or by analysis of variance for continuous measures. The association of PLA2G7 V279F with continuous outcomes was assessed by linear regression, and disease outcomes by logistic regression, with an additive [per minor (F) allele] genetic model adjusting for sex, region, age as a continuous variable and relatedness using a robust sandwich estimator method, 24 which may occasionally result in nonconvergence of the model. Based on approximately 7000 incident cases, the study had over 90% power to detect a 20% lower risk of MVE per minor (F) allele (frequency ¼ 0.05) at P < 0.01. Subgroup analyses were performed for the primary outcome, by sex, age group, region and ever regular smoking and current regular alcohol drinking status. Sensitivity analyses were performed for primary, secondary and tertiary outcomes, stratified by region without adjusting for relatedness, and using the subset of unrelated individuals. Exploratory analyses involved the addition of participants reported as undergoing revascularization procedures, or the addition of prevalent cases in combination with incident events, to the main vascular endpoints. P-values were presented unadjusted for multiple testing, but the threshold for significance at P < 0.05 was calculated using a standard Bonferroni correction by dividing 0.05 by the number of tests in each category of primary, secondary, tertiary and phenome-wide endpoints, or continuous traits. Analyses used SAS V R version 9.3 (SAS Institute Inc.).
Results
Participant characteristics and genotype distribution
Among the 91 428 study participants, the mean age at baseline was 51 years, 40% were men and 59% were from rural regions (Table 1) . Previous history of physiciandiagnosed CHD was reported by 3%, stroke or transient ischaemic attack by 2%, diabetes by 6% and hypertension by 12% of participants. Use of antihypertensive medication or statins was reported by 5% and 0.2% of participants, respectively. Baseline characteristics were generally similar between the whole CKB cohort of 512 891 participants and the randomly selected genotyped sample. Overall, 9691 (10.6%) participants had at least one copy of the loss-of-function variant. Participant baseline characteristics did not vary by PLA2G7 V279F genotype, except for modest differences in the proportions from urban regions and reporting regular alcohol consumption, and mean physical activity level (Table 1) . Assessed using the reduced dataset excluding first-degree relatedness, PLA2G7 V279F frequency was 5% overall, but varied from 3% to 7% by region (P-heterogeneity < 0.0001), and genotype distribution within each of the 10 regions did not deviate from Hardy-Weinberg equilibrium (eTable 1, available as Supplementary data at IJE online).
Association of PLA2G7 V279F with continuous traits
There were no differences by genotype in baseline physical measurements, including blood pressure, adiposity and lung function, after adjustment for sex, age, region, relatedness and multiple testing ( Table 2) . Random blood glucose level was assessed among participants not reporting a previous history of diabetes and was not associated with genotype. Figure 1 compares the risk of incident reported MVE associated with PLA2G7 V279F among 7141 cases and 81 489 controls without vascular disease at baseline or during follow-up. As our preliminary report showed, 19 there was no association of PLA2G7 V279F with MVE with an OR per minor (F) allele of 0.98 (95% CI 0.90-1.06, P ¼ 0.63). Although PLA2G7 V279F showed an association with regular alcohol drinking, a possible confounder, adjusting for drinking status did not change the results (0.98, 0.91-1.07). Furthermore, there was no difference in association with MVE between subgroups defined by sex, 10-year age group, region, ever regular smoking status or current regular drinking (Figure 2) . The loss-of-function variant of PLA2G7 V279F was not associated with components of MVE: total stroke (5967 events; 1.00, 0.92-1.09); myocardial infarction (653 events; 0.91, 0.71-1.17); and vascular death (2139 events; 0.92, 0.80-1.06). Nor was there an association with major coronary events (MCE; 922 events; 0.96, 0.79-1.18), major occlusive events (5607 events; 1.01, CI 0.93-1.11), ischaemic stroke (4843 events; 1.01, 0.92-1.11), or haemorrhagic stroke (1248 events; 0.88, 0.73-1.06). Adjustment for drinking status did not change the association of MCE with PLA2G7 V279F (0.98, 0.80-1.21). Exploratory analyses assessed the effect of adding coronary revascularization events to the coronary endpoints, which increased the number of events but did not change the association with PLA2G7 V279F (MCE þ revascularization 1087 events; 0.95, 0.79-1.16; eTable 2, available as Supplementary data at IJE online). There was also no change with addition of prevalent cases of CHD, stroke or transient ischaemic attack to the incident reported vascular endpoints (MVE þ previous disease 9939 events; 0.99, 0.90-1.06; eTable 2). Sensitivity analyses for MVE and MCE stratified by region followed by meta-analysis did not alter the results (data not shown). The rs1333049 variant at the established 9p21 locus was also genotyped in study participants, and the C allele was associated with higher risk of MCE when revascularization events were included in the endpoint (1.09, 1.00-1.19, P-value ¼ 0.04; eTable 3). This is consistent with previously published cohort studies (OR ranged from 1.09 to 1.13; eTable 4) and provides a positive control for genetic analyses of coronary disease in CKB.
Association of PLA2G7 V279F with vascular diseases
Association of PLA2G7 V279F with non-vascular diseases
In analyses of other chronic diseases, no associations with PLA2G7 V279F were observed after adjustment for multiple testing (Figure 1 ). Among combined prevalent and new-onset cases of diabetes, whereas there was a lower risk of diabetes with PLA2G7 V279F (n ¼ 7031 events; OR ¼ 0.91, 95% CI 0.84-0.98), there was no association after adjustment for multiple testing. There was also a lower risk of chronic inflammatory disease (0.79, 0.55-1.14), but event numbers were low (n ¼ 339), resulting in a wide confidence interval. Likewise, there was no association of PLA2G7 V279F with combined prevalent and new-onset cases of COPD, or with incident reported chronic kidney disease, chronic liver disease, cancer or non-vascular death.
Sensitivity analyses for vascular and non-vascular disease outcomes, without adjusting for first-degree relatedness, or using the subset of 82 459 unrelated individuals, demonstrated no difference between these results and estimates obtained with adjustment for relatedness in the main analyses (eFigures 2 and 3, available as Supplementary data at IJE online).
Among the 41 distinct disease categories in the ICD-10 coded screen, there were 196 255 coded events reported during follow-up, with 38 536 (42%) participants reporting at least one categorized event. The number of cases in each category ranged from 182 (ICD-10 J45-J46: asthma) to 7 570 (ICD-10 I60-I69: cerebrovascular disease). There was no association between PLA2G7 V279F and any of the 41 disease categories (Figure 3) . Although a reduction in risk of asthma with PLA2G7 V279F was observed (182 
Discussion
This is the largest single study to investigate the association of the PLA2G7 V279F loss-of-function variant with risk of vascular diseases, and the first to investigate its effects on a wide range of disease outcomes. Among over 91 000 Chinese adults, with 11% having at least one loss-offunction variant, we found no association of PLA2G7 V279F with major vascular or coronary events or stroke subtypes. A wide range of non-vascular outcomes were also examined, and although lower risks with PLA2G7 V279F were observed for diabetes and asthma, there was no association after adjustment for multiple comparisons. Furthermore, there was no evidence of an association of PLA2G7 V279F with either vascular or non-vascular death or cardiovascular risk factors. These results suggest that genetically determined lifelong lower Lp-PLA 2 activity has no major causal effects on vascular or non-vascular diseases.
Our findings for vascular disease are consistent with null results for the association of PLA2G7 V279F with CHD reported in meta-analyses of East Asian studies 16, 17 in which the individual studies typically involved just a few hundred cases, with diverse disease definitions, varying degrees of adjustment and little information on non-coronary diseases. Inference from the literature is often complicated by publication bias, however, since some large studies have reported only the fact of non-significance 25 or reported results fully only in a subset with significant results, 26 and this has distorted which results have been included in these meta-analyses. Although a Korean study reported a Figure 2 . The association of PLA2G7 V279F with major vascular events, among subgroups. Adjusted for sex (apart from sex subgroups), study region (apart from region subgroups), age (apart from age subgroups) and relatedness. Squares represent the odds ratio (OR) per Lp-PLA 2 lowering minor (F) allele, with area inversely proportional to the variance of the log OR. Horizontal lines represent the corresponding 95% confidence intervals (CI). The diamond represents the overall OR and its 95% CI. protective effect of V279F for myocardial infarction and angiographically defined CHD in 3700 men with adjustment for conventional risk factors (OR ¼ 0.80, 95% CI 0.69-0.92, P-value ¼ 0.002), which is not inconsistent with the 95% CIs for coronary outcomes in the present study, no effect was observed among women in the Korean study, which was attributed to possible asymptomatic CHD and misclassification among controls, and the gender-specific analyses were not pre-specified. 18 Small case-control studies of stroke have also reported varying findings; [27] [28] [29] however the present study, by far the largest to assess the effects of V279F on stroke, shows no evidence of benefit, particularly for ischaemic stroke. Studies of other PLA2G7 loss-of-function variants in populations of European and African ancestry have found no evidence of effects on CHD or vascular death, although power has been limited due to low frequency of these variants. 30, 31 Results from our study are broadly in line with recent findings from randomized trials of the Lp-PLA 2 inhibitor darapladib. The STABILITY trial (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) of 15 828 patients with stable CHD reported no effect on the primary endpoint of MVE after 3.7 years of treatment [hazard ratio (HR) 0.94, 95% CI 0.85-1.03), though a modest reduction was observed for the secondary endpoint of MCE (0.90, 0.82-1.00, P ¼ 0.045). 6 Similarly, among 13 026 ACS patients treated for 2.5 years in the randomized, double-blind, placebo-controlled trial SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52), there was no effect on the primary endpoint of MCE (1.00, 0.91-1.09) or the secondary endpoint of MVE (0.99, 0.90-1.09). 7 The trials were powered to detect a 15% reduction in relative risk, whereas lifelong exposure levels may be expected to have a greater magnitude of effect on risk than intervening to lower the exposure for just a few years in later life. 32 Our study has ruled out any protective effect on MVE greater than 10% from lifelong exposure in this general population. Vascular outcomes in the present study were selected to facilitate comparison with the randomized trials. However, it is notable that there was a much higher proportion of stroke events in the CKB compared with the trials, reflecting differences in cardiovascular disease rates between populations of East Asian and of European origin. Given the heterogeneity between coronary events and different stroke subtypes, use of a composite primary outcome such as MVE may hinder detection of disease-specific effects in trials as well as genetic studies, and it is important to balance the benefits of larger numbers with that of specific disease definition. Both trials reported no benefit for stroke, concordant with findings in the present study which was well powered for stroke. However, there were fewer myocardial infarction and major coronary events (n ¼ 922) in the present study, and larger numbers of these events in CKB would be required to rule out relative risk reductions smaller than about 20% (odds ratio for MCE 0.96; 95% CI 0.79-1.18) to draw a definitive conclusion on these outcomes. Had the present results been available to complement existing epidemiological data when the STABILITY trial was designed, 33 MCE might have been chosen for the primary endpoint. However, although the primary endpoint for SOLID was changed from MVE to MCE 7 in light of the results of STABILITY, no efficacy for darapladib on either outcome was observed.
As Lp-PLA 2 activity might play a role in multiple biological pathways, we examined the effects of PLA2G7 V279F on a wide range of disease outcomes. Although there were nominal lower risks of diabetes and asthma, there was no evidence of association after adjusting for multiple testing. Furthermore, the direction of effect of PLA2G7 V279F with chronic inflammatory diseases suggested a possible pro-inflammatory effect of Lp-PLA 2 but, given the low number of events, this was not conclusive. Lp-PLA 2 inhibitor therapies have also been investigated in phase II trials for diabetic macular oedema (NCT01506895) and Alzheimer's disease (NCT0142 8453), but these outcomes were not evaluated in the present study due to insufficient numbers of reported events. The lack of increased risks of non-vascular diseases with V279F in the present study complements safety data from clinical trials of darapladib, and suggests there are no major hazards associated with lower Lp-PLA 2 activity. Although an increase in serious renal failure events (1.5% darapladib vs 1.1% placebo; HR 1.35, 95% CI 1.03-1.78) was reported in STABILITY, 6 we found no effect on the incidence of chronic kidney disease, though the number of acute renal failure events in the present study was too low to assess this outcome reliably. Nor was there an increased risk of cancer, in either the present study or the trials. Genetic variants influencing therapeutic targets cannot, however, be used to identify off-target drug effects. 34 The present study has a number of strengths, including large sample size, standardized data collection, and detailed information on a wide range of disease outcomes collected through linkage to electronic health records. However, the study was still under-powered for many outcomes examined, e.g. myocardial infarction and major coronary events, which can be addressed with further genotyping of additional CKB samples and a longer follow-up period. Extrapolation from the effects of a genetic variant to the causal role of a biomarker can be hindered if the genetic variant has pleiotropic effects (i.e. other than via the biomarker) on outcomes, which are very difficult to determine. Although such effects cannot be ruled out in the present study, PLA2G7 V279F is a functional variant close to the active domain of Lp-PLA 2 , resulting in inactive enzyme, [11] [12] [13] and no evidence for pleiotropy was found in our analyses of baseline traits. Also, developmental compensation to a functional genetic variant could potentially alter effects on outcomes, 35 but this is unlikely to have affected the present study as, although not directly assessed in the study participants, the loss of Lp-PLA 2 activity in V279F carriers is well established among East Asian adults. [11] [12] [13] Population stratification is an important consideration for Mendelian randomization studies, and although the frequency of V279F varied somewhat across the 10 CKB study regions, there was no evidence of heterogeneity of effect by region. This study, only possible in East Asians given the geographical distribution of PLA2G7 V279F, demonstrates the value different populations can bring to Mendelian randomization investigations. The CKB is uniquely placed to investigate the role of other exposures influenced by East Asianspecific variants, such as alcohol consumption and the ALDH2 loss-of-function variant.
Conclusions
This study provides new evidence that lifelong lower Lp-PLA 2 activity is unlikely to have a major causal effect on risk of vascular or non-vascular diseases in the general population, complementing findings from recent randomized trials. The use of functional genetic variants in blood-based prospective cohorts with linkage to electronic health records, such as the CKB and UK Biobank, 36 represents a valuable approach for assessment of potential drug targets. The accumulation of further disease events over the next 5-10 years, in combination with clinical event adjudication and subphenotyping, will substantially increase power to detect genetic (and non-genetic) associations in the CKB. Genomewide analysis currently ongoing in the CKB includes about 80 000 loss-of-function variants which may represent important pathways for development of novel therapies, and their effects on target outcomes can be evaluated and potential alternative indications or safety issues may also come to light. Additionally, for common, chronic diseases such as major vascular diseases which may have heterogeneous aetiology, genetically identified subtypes could help guide more efficient and targeted clinical trials. Future drug development and repositioning could benefit greatly from such information, especially if conducted in the early stages of clinical development, before undertaking large-scale clinical trials.
